Abstract: The present invention relates to a method for determining the presence or absence of at least one promoter in a cancerous biological sample relative to a non-cancerous biological sample. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method for modulating the activity of at least one cancer-associated promoter in a cell, a method for modulating the immune response of a subject to cancer, a method for determining the presence of at least one cancer-associated promoter in a cancerous biological sample relative to a non-cancerous biological sample and a biomarker for detecting cancer in a subject.

Abstract: Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

Abstract: Provided herein are systems and methods of controlling the transmission of messages in a networked environment. A server can send a set of instructions to a user device associated with a user, each of the instructions to present a message in at least one of a set of variants. The server can receive a set of responses corresponding to the instructions, each of the responses by the user to a respective presentation of the message in at least one of the variants. The server can determine a respective performance measure of the message in each variant using the responses and can update a selection model responsive to the responses. The server can select variant from the based on the performance measure for the variant. The server can transmit a second instruction to the user device associated with the user to present the message in the selected variant.

Abstract: Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

Abstract: The present invention relates to a method of identifying a patient suffering from cancer as benefiting or not benefiting from immune checkpoint inhibition therapy comprising the steps of measuring an expression level of one or more preselected markers in a cancerous biological sample obtained from the patient, identifying a differentially expressed alternative promoter based on the expression level of the one or more preselected markers, calculating an alternative promoter usage score and identifying the patient as benefiting or not benefiting from immune checkpoint inhibition therapy using the alternative promoter usage score. The present invention also relates to a biomarker for excluding a patient suffering from cancer from immune checkpoint inhibition therapy.

Abstract: The present invention relates to a method for determining the presence or absence of at least one promoter in a cancerous biological sample relative to a non-cancerous biological sample. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method for modulating the activity of at least one cancer-associated promoter in a cell, a method for modulating the immune response of a subject to cancer, a method for determining the presence of at least one cancer-associated promoter in a cancerous biological sample relative to a non-cancerous biological sample and a biomarker for detecting cancer in a subject.

Abstract: Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

Abstract: In overview, the technology is primarily directed to the implementation of linked gaming in respect of a plurality of gaming machines. In particular, a controller device is disclosed, this controller device being adapted to enable the management of a plurality of linked games via a single piece of hardware. This is achieved in part by virtualization of jackpot controllers within the controller device. More specifically, a user is enabled to configure a plurality of virtual jackpot controllers by way of interaction with a graphical user interface, and select compatible electronic gaming machines to participate in a linked game provided by a given one of the virtual jackpot controllers.

Abstract: Technology described herein includes an arrangement whereby a hardware-based solution is implemented to enable mirroring of NVRAM data in a master server directly to NVRAM in a sleeper server. Both the master server and sleeper server implement a like motherboard unit, which is configured to implement the mirroring technology. That is, the roles of master and sleeper may be reversed. The master server includes a hardware module that monitors (but does not affect) NVRAM operations at the master server, and replicates those operations via a high speed communications link, such as a fiber optic link, to the sleeper server. The term “high speed communications link” refers to a link with at least 2.5 gigabit speed, and preferably at least 5 gigabit speed. The sleeper server is configured to, when in sleeper mode, suspend control of its own NVRAM module. Instead, the NVRAM module is controlled by a module that is configured to receive NVRAM operations via the fiber optic link, and apply those operations.

Abstract: The present invention relates to a method for determining or making of a prognosis if a patient has cancer or is at an increased risk of having cancer, the method comprising testing for the presence of one or more cancer-associated fusion genes, or proteins derived thereof, in a sample obtained from a patient. More specifically, the present invention relates to fusion genes CLEC16A-EMP2, SNX2-PRDM6, MLL3-PRKAG2, DUS2L-PSKH1 and CLDN18-ARHGAP26 in gastric cancer. Use of the method and a kit when used in the method are also provided.

Abstract: In overview, the technology is primarily directed to the implementation of linked gaming in respect of a plurality of gaming machines. In particular, a controller device is disclosed, this controller device being adapted to enable the management of a plurality of linked games via a single piece of hardware. This is achieved in part by virtualization of jackpot controllers within the controller device. More specifically, a user is enabled to configure a plurality of virtual jackpot controllers by way of interaction with a graphical user interface, and select compatible electronic gaming machines to participate in a linked game provided by a given one of the virtual jackpot controllers.

Abstract: The present invention relates to a pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP-4) or its gene expression. The present invention also relates to methods of treating cancer and prognostic methods.

Abstract: In overview, the technology is primarily directed to the implementation of linked gaming in respect of a plurality of gaming machines. In particular, a controller device is disclosed, this controller device being adapted to enable the management of a plurality of linked games via a single piece of hardware. This is achieved in part by virtualization of jackpot controllers within the controller device. More specifically, a user is enabled to configure a plurality of virtual jackpot controllers by way of interaction with a graphical user interface, and select compatible electronic gaming machines to participate in a linked game provided by a given one of the virtual jackpot controllers.

Abstract: Technology described herein includes an arrangement whereby a hardware-based solution is implemented to enable mirroring of NVRAM data in a master server directly to NVRAM in a sleeper server. Both the master server and sleeper server implement a like motherboard unit, which is configured to implement the mirroring technology. That is, the roles of master and sleeper may be reversed. The master server includes a hardware module that monitors (but does not affect) NVRAM operations at the master server, and replicates those operations via a high speed communications link, such as a fiber optic link, to the sleeper server. The term “high speed communications link” refers to a link with at least 2.5 gigabit speed, and preferably at least 5 gigabit speed. The sleeper server is configured to, when in sleeper mode, suspend control of its own NVRAM module. Instead, the NVRAM module is controlled by a module that is configured to receive NVRAM operations via the fiber optic link, and apply those operations.

Abstract: There is provided a grouping for classifying a gastric cancer tumor sample obtained from a patient suffering or suspected to suffer from gastric cancer, wherein the grouping comprises an invasive subtype, a proliferative subtype and a metabolic subtype. There is also provided a predictor and methods of using the grouping.

Abstract: The present invention relates to a pharmaceutical composition comprising an anti-cancer drug and an inhibitor of bone morphogenetic protein 4 (BMP-4) or its gene expression. The present invention also relates to methods of treating cancer and prognostic methods.

Abstract: In overview, the technology is primarily directed to the implementation of linked gaming in respect of a plurality of gaming machines. In particular, a controller device is disclosed, this controller device being adapted to enable the management of a plurality of linked games via a single piece of hardware. This is achieved in part by virtualization of jackpot controllers within the controller device. More specifically, a user is enabled to configure a plurality of virtual jackpot controllers by way of interaction with a graphical user interface, and select compatible electronic gaming machines to participate in a linked game provided by a given one of the virtual jackpot controllers.

Abstract: Fluorescent screens and display systems and devices based on such screens using at least one excitation optical beam to excite one or more fluorescent materials on a screen which emit light to form images. The fluorescent materials may include phosphor materials and non-phosphor materials such as quantum dots. A screen may include a multi-layer dichroic layer.

Abstract: The present invention in one aspect relates to a method for treating cancer or enhancing a cancer treatment, the method comprising inhibiting the expression of an oligonucleotide encoding for a protein selected from the group consisting of OLFM4, SP5, TOB1, ARID1A, FBN1 and HAT1, by administering to a mammal in need of cancer treatment an effective amount of at least one silencing oligonucleotide comprising a binding motif for binding to the oligonucleotide encoding for a protein.

Abstract: The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient.